Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma

Background & Aims: The combination of atezolizumab and bevacizumab offers a novel approach to immunomodulation, showing efficacy as a primary treatment in advanced hepatocellular carcinoma (HCC). Concerns about graft safety and rejection have limited its exploration in the neoadjuvant settin...

Full description

Saved in:

Bibliographic Details
Main Authors:	Parissa Tabrizian, Rebecca Marino, Sherrie Bhoori, Marcus Zeitlhoefler, Neil Mehta, Vanessa Banz, Salvatore Gruttadauria, Massimo Iavarone, Chiara Mazzarelli, Nicolò Simonotti, Francis Yao, Vincenzo Mazzaferro, Josep M. Llovet
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	JHEP Reports
Subjects:	hepatocellular carcinoma liver transplantation immunotherapy atezolizumab bevacizumab Immune Checkpoint Inhibitors
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589555924002507
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
by: Hironori Ochi, et al.
Published: (2025-01-01)

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
by: Jie Dai, et al.
Published: (2025-01-01)

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

Three effective cases of transcatheter arterial embolization after atezolizumab and bevacizumab treatment for hepatocellular carcinoma: a case report
by: Koji Rinka, et al.
Published: (2025-01-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

To evaluate the efficacy of subconjunctival bevacizumab injection in vascular pterygium before surgical excision in preventing recurrence comparing with bare sclera technique
by: Nusrat Shaheen, et al.
Published: (2025-01-01)

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy
by: Tian He, et al.
Published: (2025-01-01)

Efficacy of Sub-Conjunctival Injection of Mitomycin C Versus Bevacizumab in Pterygium Treatment: Pakistani Population
by: Amber khalid, et al.
Published: (2025-01-01)

Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study
by: Bin Yin, et al.
Published: (2025-01-01)

Clinical characteristics, diagnosis, treatment, and prognosis of Atezolizumab-induced encephalitis, aseptic meningitis or meningoencephalitis
by: Qingzi Yan, et al.
Published: (2025-01-01)

Intra-operative Intravitreal Bevacizumab For Patients With Diabetic Macular Edema Undergoing Phacoemulsification with Foldable IOL Implantation
by: Haider Ali Chaudhry, et al.
Published: (2024-06-01)

J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan
by: Eisaku Miyauchi, MD, PhD, et al.
Published: (2025-03-01)

Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review
by: Ke Chen, et al.
Published: (2025-02-01)

Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion
by: Carmine Pinto, et al.
Published: (2025-01-01)

IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?
by: S. V. Orlov, et al.
Published: (2016-06-01)

Modified autologous neurosensory retinal transplantation and bevacizumab injection in primary extra-large chronic macular holes
by: Hossein Ashraf, et al.
Published: (2025-06-01)

Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
by: Atsushi Naganuma, et al.
Published: (2025-01-01)

Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols
by: Sattar Saima, et al.
Published: (2019-03-01)

Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE‐4.5 study
by: Susanne Klein‐Scory, et al.
Published: (2025-02-01)

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01)

PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
by: He Z, et al.
Published: (2025-01-01)

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence
by: Yuta Yamanaka, et al.
Published: (2024-12-01)

Prognostics optical coherence tomography biomarker in macular oedema secondary to retinal vein occlusion
by: Andrea R. Silitonga, et al.
Published: (2025-01-01)

Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab
by: Jeevan Kumar, et al.
Published: (2012-01-01)

PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS
by: M. Y. Frolov, et al.
Published: (2016-09-01)

Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer
by: Akira Tsunoda, et al.
Published: (2022-01-01)

The Effect of Bevacizumab and Propranolol on Nasal Polyposis
by: Yuksel Olgun, et al.
Published: (2022-01-01)

Photopsias during Systemic Bevacizumab Therapy
by: Heather Leisy, et al.
Published: (2016-01-01)

Bevacizumab: A Rare Cause of Nonischemic Cardiomyopathy
by: Oreoluwa Oladiran, et al.
Published: (2018-01-01)

In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery
by: Yuanyuan Zhang, et al.
Published: (2019-01-01)

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab
by: Deli Krizova, et al.
Published: (2014-01-01)

Dynamic Modeling of the Angiogenic Switch and Its Inhibition by Bevacizumab
by: Dávid Csercsik, et al.
Published: (2019-01-01)

Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2015-05-01)

Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2007-03-01)

Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2007-03-01)

Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2015-05-01)

Atezolizumab neutralizing assay development: a novel way of evaluating assay cutpoint after sample pretreatment
by: Rachel Melendez, et al.
Published: (2025-02-01)

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture
by: J. Fernando Arevalo, et al.
Published: (2011-01-01)

Simultaneous Subconjunctival Triamcinolone and Bevacizumab Injections for Management of Blepharokeratoconjunctivitis in Children
by: Chu Luan Nguyen, et al.
Published: (2018-01-01)